Comparative Pharmacodynamics and Pharmacokinetics of Cimetidine and Ranitidine

  title={Comparative Pharmacodynamics and Pharmacokinetics of Cimetidine and Ranitidine},
  author={Douglas A. Richards},
  journal={Journal of Clinical Gastroenterology},
  • D. Richards
  • Published 1 December 1983
  • Medicine, Biology
  • Journal of Clinical Gastroenterology
Ranitidine and cimetidine are competitive antagonists of histamine at H2-receptor sites in the gastric mucosa. Both drugs reduce output of basal and stimulated gastric acid and pepsin secretion in normal healthy subjects and duodenal ulcer patients. Pharmacodynamic and pharmacokinetic differences exist between the drugs, some of times more potent inhibitor of gastric secretions and also causes a greater reduction in intragastric acidity of nocturnal secretions after usual therapeutic doses… 

Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Therapeutic trials involving several thousands of patients with peptic ulcer disease confirm that ranitidine 300mg daily administered orally in single or divided doses is at least as effective as cimetidine 800 to 1000mg daily in increasing the rate of healing of duodenal and gastric ulcers.

Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.

Pharmacokinetics and bioavailability of famotidine, a new H2-receptor antagonist, were investigated in healthy subjects in five clinical studies and found that renal excretion was the major route of elimination.

Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans

It is indicated that ranitidine may accelerate the gastric transit of indigestible solid dosage formulations by approximately 1 hour.

A comparison of the effects of treatment with either famotidine 40 mg or cimetidine 800 mg nocte on gastric acid secretion and serum gastrin

With famotidine there was inhibition of stimulated gastric acid secretion at 3 and 24 days after completion of treatment, and fasting serum gastrin measured 12 h after dosing was not significantly altered by either drug.

Histamine and the nasal vasculature: the influence of H1 and H2-histamine receptor antagonism.

It is concluded that the histamine H1-receptor has the greatest effect on changes in nasal vascular permeability induced by topical histamine, whereas the H2-receptors has the largest effect on nasal obstruction.